PDCI & H3 Survey on Private Payer Product Listing Agreements Now “Closed” for Responses
As noted in the June 24th TargetPharma, PDCI Market Access (www.pdci.ca) and H3 Consulting (www.hthree.ca) are collaborating on a survey to gauge the interest, expectations, and experience associated with private payer product listing agreements (PLAs).
Surveys were sent to a targeted list of respondents that included pharmaceutical manufacturers, insurers, and pharmacy benefit managers on June 29, 2015. Participants were given 3 weeks to respond, and the survey was officially closed on Friday, July 17, 2015.
PDCI and H3 would like to thank those who participated in this initiative and provided their perspective on this subject. We are pleased to announce that we received 27 responses (from 19 manufacturers and 8 private insurers) and are currently analyzing them.
Our analysis will provide insights on topics such as the:
- prevalence of private payer PLAs;
- types of agreements being negotiated;
- motivation for negotiating PLAs; and
- level of interest in negotiating private PLAs in the future.
Please contact Courtney Abunassar (Courtney.Abunassar@pdci.ca), PDCI’s Manager of Market Access and Policy Research or Chris Bonnett (email@example.com), Principal of H3 Consulting if you have any questions about this research.